Project Nexus

RGMA – PwC Status Update

18 March 2016



Contents

- 1. Update on RGMA Review
- 2. Key Messages
- 3. Next Steps

This document has been prepared only for Ofgem and solely for the purpose and on the terms agreed with Ofgem in our statement of work dated 11 November 2015 and under the framework agreement dated 26 August 2015. We accept no liability (including for negligence) to anyone else in connection with our work or this document.

© 2016 PricewaterhouseCoopers LLP. All rights reserved. In this document, "PwC" refers to the UK member firm, and may sometimes refer to the PwC network. Each member firm is a separate legal entity. Please see www.pwc.com/structure for further details.

1. Update on RGMA Review

Requirement

The objective of the review is to assess the robustness of Xoserve's RGMA UAT delivery plan to establish **a high degree of confidence** in the date when RGMA functionality can be delivered into Market Trials.

Context

At the PNSG on 22 February, Xoserve clarified that the plan to deliver RGMA into Market Trials on 1 March would not be met, after previously alerting the PNSG that this was a delivery risk. It was agreed at the PNSG on 22 February, that on 14 March, Xoserve would share their plan to deliver RGMA as soon as possible into Market Trials and they identified a target date of 15 April 2016.

Due to the agenda change to the 14 March PNSG, the RGMA update from Xoserve was de-scoped but, it was agreed that PwC, in their extended project management and assurance role, would conduct a review into Xoserve's plans to complete their UAT and deliver RGMA against the objective stated above.

The review commenced on 16 March 2016. This document is the agreed interim status update for the final report which is scheduled on 24 March 2016.

PwC view as at 18 March 2016

Complete delivery of RGMA functionality by 15 April 2016 **is highly ambitious** without a reduction/prioritisation in either test and/or functionality scope.

Xoserve comments

Work is progressing on track to deliver the changes required to RGMA functionality (ONJOB & ONUPD) and to complete Xoserve acceptance testing by 15th April. Xoserve, Wipro and Baringa are tracking the Build and FUT delivery plan at a granular level to allow Acceptance Testing to commence on 28th March. Analysis of the acceptance testing required is complete and a granular testing plan/schedule being developed and due to completed on 24th March.

As discussed at PNSG on 14th March, DUC is not able to be delivered into MT for 15th April and work has ceased on this element of functionality following discussions with Ofgem. Formal governance to remove this from scope will be progressed through UK Link Committee.

2. Key Messages

On 16 March, PwC attended a kick off meeting with Xoserve, Baringa and Wipro to confirm the scope of the review as well as gain an understanding of the current position of RGMA delivery into Market Trials, in further detail.

Due to the current point in Xoserve's plan, build is not yet complete for outstanding defects and clarifications, therefore, the earliest date that it will be possible to say, with a degree of confidence, whether 15 April 2016 is fully achievable, is 24 March 2016. Key indicators of achievability of delivering the <u>full</u> RGMA functionality into Market Trials by 15 April are:

- **UAT Test Plan**: With the assistance of Baringa and Wipro, Xoserve are currently conducting a detailed planning exercise to determine the volume of UAT testing to be conducted and associated resource requirements for the UAT test phase (scheduled for 28/03/16 15/04/16). This exercise is scheduled for completion **by 24 March latest**.
- Completion of build by 24/03/16: Defects and clarifications (additional scenarios which require a change to SAP code or functionality) are expected to complete design, build and functional testing by 24 March. Detailed UAT test plans for these areas are vet to be completed but, are scheduled for completion in advance of 24 March.

Indicators of partial delivery of RGMA (but 100% of core RGMA) into Market Trials by 15 April include: UAT Test Plan complete by 24 March (as above) and:

• **Delivery of remaining core RGMA functionality:** Over 70% of RGMA functionality is complete (built and tested (UAT) with a proportion already delivered into the Market Trials environment on 1 March. According to Xoserve, 80% of core RGMA functionality has been built and UAT tested. The majority of the outstanding build and test for RGMA relates to non-core RGMA functionality. This presents an option to deliver all core RGMA functionality into the Market Trials environment by 15 April (if complete) and the remainder at a later date.

Note 1: Baringa continue to work closely with Xoserve to provide continuous feedback and advice on all areas of the RGMA delivery plan. There is, however, no intention to produce a formalised output regarding this involvement. Baringa will continue to feed into PNSG reporting on behalf of Xoserve.

Note 2: Xoserve proposed the de-scope of Data Update Code ('DUC') functionality at PNSG on 14/03/16. Development work in this area has now ceased as the de-scope will be put forward for formal approval at UK Link Committee on 23 March. Xoserve do not expected to have **ANY** adverse impact on the delivery of RGMA functionality.

3. Next Steps

In order to provide a date as to when RGMA functionality (full or partial) can be delivered into Market Trials, with a high degree of confidence, PwC will conduct the following activities:

Activity	Purpose	Date	
Review of latest Clarification log and extract of outstanding defects from HPQC.	 Gain an idea of outstanding effort required to complete RGMA via:- Volume of clarifications and defects; Nature of clarifications and defects (core/non core, SAP/AMT); Anticipated build and functional unit test completion dates; and Number of test scenarios predicted for each clarification. 	18/03/16	
Understand the existing build position of RGMA.	 What scenarios are included within the 70% of RGMA which has been built; What scenarios are included within core and non-core RGMA; and What parts of core RGMA constitute the build components currently and which do not. 	21/03/16	
Please note: The implications of partial RGMA delivery into Market Trials has yet to be discussed with market participants			
Attendance at detailed planning meetings between Xoserve, Baringa and Wipro.	Understand planning process and avoid duplication of effort by walking through the process after the event.	21/03/16 – 24/03/16	
Confirmation that UKLC approval has been sought for Data Update Code ('DUC') descope with approval scheduled for the following week.	If approval not provided, there will be a direct impact upon the achievability of delivering RGMA within proposed timeframes.	23/03/16	
Confirm design and build for defects and clarifications is complete (and specifically that the 20% of remaining core-RGMA functionality is built).	 Confirm that all build activity is complete (as scheduled) prior to UAT commencing. Review baselined Clarification log and compare volume and nature of clarification against earlier version of log to assess increase/decrease in proposed effort for testing. 	24/03/16	

Project Nexus PwC

3. Next Steps continued

Activity	Purpose	Date
Review of detailed testing plan.	 Determine whether the plan has appropriately considered the following:- Volume of testing to be conducted within three week test phase; Anticipated time required to test scenarios for each clarification/defect with a particular focus on those requiring SAP or AMT fixes; Proportion of test scenarios relating to non core scenarios and associated effort; Inclusion of regression testing elements within individual test plans; and Any potential change to existing file formats. 	24/03/16

PwC to communicate findings of work conducted above to OFGEM by 24 March 2016.

Project Nexus PwC



This publication has been prepared for general guidance on matters of interest only, and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, PricewaterhouseCoopers LLP, its members, employees and agents do not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.